Immune insights could pave way for new AML therapies

NCT ID NCT06279572

Recruiting now Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is collecting blood and bone marrow samples from 80 adults with acute myeloid leukemia (AML) who are starting treatment with azacitidine plus venetoclax. Researchers want to understand how the immune system responds to this chemotherapy combination. The goal is to find clues that could help develop future T-cell based immunotherapies for AML.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could point toward new immune-based treatments for acute myeloid leukemia.
What could go wrong: This is an early observational study, not a treatment trial. It may not lead directly to new therapies, and results may not apply to all AML patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Show contact details

Locations

Mayo Clinic in Arizona
NOT_YET_RECRUITING

Scottsdale, Arizona, 85259, United States

Contact Email: •••••@•••••
Mayo Clinic in Florida
RECRUITING

Jacksonville, Florida, 32224-9980, United States

Contact Email: •••••@•••••
Mayo Clinic in Rochester
NOT_YET_RECRUITING

Rochester, Minnesota, 55905, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.